XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19 2017 - 7:00AM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery,
development and licensing of therapeutic antibodies, today
announced that Jim Neal, Chief Executive Officer, will present the
Company’s strategic initiatives and value drivers at the Cantor
Fitzgerald Global Healthcare Conference on Tuesday, September 26,
2017, at 1:05 p.m. ET. The conference is being held at the
InterContinental New York Barclay Hotel in New York City.
A live audio webcast of the presentation can be accessed in the
Investors section of XOMA's website at www.xoma.com. An
archived version of the webcast will be available via replay for 90
days following the presentation.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and
technologies that are the subject of licenses the Company has in
place with other biotech and pharmaceutical companies. Many of
these licenses are the result of the Company's pioneering efforts
in the discovery and development of antibody therapeutics. There
are more than 20 such programs that are fully funded by partners
and could produce milestone payments and royalty payments in the
future. For more information, visit www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, including statements regarding the potential of XOMA’s
portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time.
These statements are based on assumptions that may not prove
accurate, and actual results could differ materially from those
anticipated due to certain risks inherent in the biotechnology
industry and for companies engaged in the development of new
products in a regulated market. Potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-K and in other SEC filings. Consider such
risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
Investor contact:Luke
HeaglePure Communications+1
910-726-1372lheagle@purecommunications.com
Media contact:Julie NormartPure
Communications+1
415-946-1087jnormart@purecommunications.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024